Marker Therapeutics Inc (MRKR)

[microcapbiotech]

So, in the AML trial, out of 8 MRD+ patients, 3 went to MRD-, but I guess not good enough as MRKR is pretty much saying that they are changing the AML trial to use commercially available leukapheresis material and that NOW the FIRST patient will be treated in the second half of 2024.
Instead NOW, MRKR will prioritize the MT-601 trial for lymphoma ... and they go on to repeat all the data that we already knew about the first lymphoma patient. NO new data on lymphoma patients 2 or 3 or 4 or etc. if they have been enrolled or treated yet.
All in All, sounds like we are ditching a Phase 2 trial to focus on a Phase 1 trial ... which means we are being pushed back even further in time.
????????????????????